Meeting
2017 Gastrointestinal Cancers Symposium
Nintedanib (N) plus best supportive care (BSC) versus placebo (P) plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Subanalysis of the phase III LUME-colon 1 study in pts by prior regorafenib (R) treatment.
Authors
Heinz-Josef Lenz
USC Norris Comprehensive Cancer Center, Los Angeles, CA
Heinz-Josef Lenz , Takayuki Yoshino , Guillem Argiles , Timothy Iveson , Javier Sastre , Mark Harrison , Howard John Lim , Niall C. Tebbutt , Marc Peeters , Taroh Satoh , Christian Dittrich , Mouna Sassi , Arsene-Bienvenu Loembe , Eric Van Cutsem
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02149108
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 660)
DOI
10.1200/JCO.2017.35.4_suppl.660
Abstract #
660
Poster Bd #
G12
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
LUME-Colon 1: A double-blind, randomized phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer (CRC) refractory to standard therapies.
First Author: Heinz-Josef Lenz
Poster
2017 Gastrointestinal Cancers Symposium
Nintedanib (N) plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies: Health-related quality of life (HRQoL) results of the Phase III LUME-Colon 1 study.
First Author: Heinz-Josef Lenz
Poster
2018 ASCO Annual Meeting
A phase I/II study of nintedanib and capecitabine in refractory metastatic colorectal cancer.
First Author: Patrick McKay Boland
Poster
2017 Gastrointestinal Cancers Symposium
A phase I/II study of nintedanib and capecitabine in refractory metastatic colorectal cancer.
First Author: Patrick McKay Boland